<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162367</url>
  </required_header>
  <id_info>
    <org_study_id>SCARM-Skin-002</org_study_id>
    <nct_id>NCT03162367</nct_id>
  </id_info>
  <brief_title>Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn</brief_title>
  <official_title>Comparison Study OF Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Second Degree Burn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCARM Institute, Tabriz, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SCARM Institute, Tabriz, Iran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different medical treatments are available for treatment of skin burns such as skin grafts
      and silver sulfadiazine ointment. These treatments are used for second degree burn as routine
      technique in burns units. Cell therapy is a new approach for treatment of skin disease.In
      this study we use autologous epidermal cell suspension to achieve better cosmetic and
      functional results in treatment of second degree burn.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study 20 patients in Burn Department of Sina Hospital Tabriz, with at least 2 areas
      of second degree burn randomly choose. First skin samples are taken from normal skin by 4mm
      punch and send to the laboratory for preparation of epidermal cell suspension and this
      suspension is transferred to the one area of second degree burn in each patient and the other
      area in the same patient dresses by silver sulfadiazine ointment. The dressing changes are
      followed up for 12h for first assessment of therapy until 10th day after intervention. In the
      days of 5, 10, 15 and 20 the percentage of re-epithelization for each treatment will be
      measured. After 2 months, patients are visited and any complications check for scar
      formation, pain, post inflammatory hyper-pigmentation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2018</start_date>
  <completion_date type="Anticipated">December 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in re-epithelization rate with autologous epidermal cell suspension graft from Baseline</measure>
    <time_frame>up to 20 days</time_frame>
    <description>Measurement the percentage of re-epithelization ( 0-30%=poor; 30-60%=moderate; 60-90%=good; &gt;90%=complete)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in re-epithelization rate with silver sulfadiazine ointment from Baseline</measure>
    <time_frame>up to 20 days</time_frame>
    <description>Measure percentage of re-epithelization ( 0-30%=poor; 30-60%=moderate; 60-90%=good; &gt;90%=complete)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar formation</measure>
    <time_frame>After 2 month</time_frame>
    <description>Observe patient and take photo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post inflammatory hyperpigmentation</measure>
    <time_frame>After 2 month</time_frame>
    <description>Observe patient and take photo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Autologous epidermal cell suspension group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Silver sulfadiazine ointment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous epidermal cell suspension</intervention_name>
    <description>First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn</description>
    <arm_group_label>Autologous epidermal cell suspension group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silver sulfadiazine ointment</intervention_name>
    <description>the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day</description>
    <arm_group_label>Silver sulfadiazine ointment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy patient with second degree burn admitted in burn unit

        Exclusion Criteria:

          -  Pregnancy-lactation

          -  Immunosuppression like receiving chemotherapy or radiotherapy

          -  Patient unsatisfied to going on study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Reza Ranjkesh, MD, Dermatologist</last_name>
    <role>Study Director</role>
    <affiliation>SCARM institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sahar Ebrahimi, MD</last_name>
    <phone>04135498236</phone>
    <email>ebrahimi.sahar1@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sina hospital</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sahar Ebrahimi, MD, Dermatologist</last_name>
      <phone>0914 166 7012</phone>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>You HJ, Han SK. Cell therapy for wound healing. J Korean Med Sci. 2014 Mar;29(3):311-9. doi: 10.3346/jkms.2014.29.3.311. Epub 2014 Feb 27. Review.</citation>
    <PMID>24616577</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao H, Chen Y, Zhang C, Fu X. Autologous epidermal cell suspension: A promising treatment for chronic wounds. J Tissue Viability. 2016 Feb;25(1):50-6. doi: 10.1016/j.jtv.2015.11.003. Epub 2015 Dec 8. Review.</citation>
    <PMID>26706649</PMID>
  </results_reference>
  <results_reference>
    <citation>Mcheik JN, Barrault C, Levard G, Morel F, Bernard FX, Lecron JC. Epidermal healing in burns: autologous keratinocyte transplantation as a standard procedure: update and perspective. Plast Reconstr Surg Glob Open. 2014 Oct 7;2(9):e218. doi: 10.1097/GOX.0000000000000176. eCollection 2014 Sep. Review.</citation>
    <PMID>25426401</PMID>
  </results_reference>
  <results_reference>
    <citation>Gardien KL, Marck RE, Bloemen MC, Waaijman T, Gibbs S, Ulrich MM, Middelkoop E; Dutch Outback Study Group1. Outcome of Burns Treated With Autologous Cultured Proliferating Epidermal Cells: A Prospective Randomized Multicenter Intrapatient Comparative Trial. Cell Transplant. 2016;25(3):437-48. doi: 10.3727/096368915X689569. Epub 2015 Sep 28.</citation>
    <PMID>26419871</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn</keyword>
  <keyword>Epidermal cell suspension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

